Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Exploration of interethnic variation in the ibuprofen metabolizing enzyme CYP2C9: a cautionary guide for treatment of COVID-19 symptoms

Ammar Ali Almarzooq
doi: https://doi.org/10.1101/2021.01.09.21249508
Ammar Ali Almarzooq
1Galore Consultancy, Flat 12, Building 144, Road 336, Block 314, Manama, Bahrain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ammar@galoreconsultancy.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Coronavirus disease 2019 (COVID-19), is a rapidly spreading infectious illness that causes a debilitating respiratory syndrome. Supportive therapy remains the standard for mild-to-moderate cases, including treatment with non-steroidal anti-inflammatory drugs (NSAIDs) e.g. ibuprofen, however such medications may increase COVID-19 complications when used in patients with acute viral respiratory infections. P450 enzyme CYP2C9 are known to be involved in the metabolism of NSAIDs, however, their pharmacogenetic data are limited. This study aims to better understand the genetic landscape of CYP2C9 sequence variation across different ethnic and geographic groups, in correlation with ibuprofen dosing guidelines. A cohort of 101 Jordanian Arab samples were retrospectively recruited and genotyped using Affymetrix DMET Plus Premier Package. This study identified 18 single nucleotide polymorphisms (SNPs) within CYP2C9 in these Jordanian Arabs, within the context of over 100,000 global subjects in 417 published reports. Genetic structure analysis across populations revealed that Jordanian Arabs share the closest CYP2C9 sequence homology to Near East and European populations. However, European populations are 7.2x more likely to show impaired ibuprofen metabolism than Sub-Saharan populations, and 4.5x more likely than East Asian ancestry populations.. This is the most comprehensive and up-to-date analysis for CYP2C9 allele frequencies across multi-ethnic populations world-wide. The use of modern genomic tools coupled with a proactive assessment of the most likely gene-drug candidates will lead to a better understanding of the role of pharmacogenetics for COVID-19 and more effective treatments.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding was available for this study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board (IRB) of the Jordan University of Science and Technology approved this study on 4/7/2013 under registration number 67/2/2013.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets generated during the current study are included in the supplementary files.

https://api.pharmgkb.org/v1/download/file/attachment/CYP2C9_frequency_table.xlsx

https://api.pharmgkb.org/v1/download/file/attachment/CYP2C9_Diplotype_Phenotype_Table.xlsx

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Exploration of interethnic variation in the ibuprofen metabolizing enzyme CYP2C9: a cautionary guide for treatment of COVID-19 symptoms
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Exploration of interethnic variation in the ibuprofen metabolizing enzyme CYP2C9: a cautionary guide for treatment of COVID-19 symptoms
Ammar Ali Almarzooq
medRxiv 2021.01.09.21249508; doi: https://doi.org/10.1101/2021.01.09.21249508
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Exploration of interethnic variation in the ibuprofen metabolizing enzyme CYP2C9: a cautionary guide for treatment of COVID-19 symptoms
Ammar Ali Almarzooq
medRxiv 2021.01.09.21249508; doi: https://doi.org/10.1101/2021.01.09.21249508

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (415)
  • Dentistry and Oral Medicine (70)
  • Dermatology (47)
  • Emergency Medicine (144)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4856)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (676)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (629)
  • Health Policy (320)
  • Health Systems and Quality Improvement (204)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5339)
  • Intensive Care and Critical Care Medicine (330)
  • Medical Education (93)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (686)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (208)
  • Oncology (439)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (89)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (780)
  • Public and Global Health (1816)
  • Radiology and Imaging (324)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)